Full Press Release Details
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the.
AXSM
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the
Key Takeaway: Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the